Source ForPressRelease.com

Shycocan, a breakthrough virus-attenuation device invented and manufactured in India, has been launched in the UAE at the International Conference of Pharmacy & Medicine (ICPM) held at Sharjah. This marks the Middle East debut of the product, the first of its kind in the world, that is seeing a robust demand from institutional buyers across the world in times of the raging Coronavirus pandemic.



The cylindrical device, Shycocan, is scientifically evidenced to neutralise and help curb the spread of the Coronavirus and Influenza family of viruses in indoor spaces with 99.9% efficacy, enabling schools, colleges, homes and businesses like hospitals, hotels, offices, restaurants, auditoriums, transportation, retail and airports get back to normal and serve the customers in a safe environment.



Remarkably, Shycocan also works on all current and future variants and mutants of these viruses, protecting people's health and saving millions of hours of lost productivity.



Alok Sharma, Chief Executive Officer, Shycocan Corporation, said, "The world faced one of its biggest challenges with the pandemic, bringing us all to a standstill. More livelihoods than lives have been lost, in fact, close to a billion at the last count. Science, technology and innovation are going to play a big role in helping us reclaim our lives and work safely. We are delighted to launch the pathbreaking one- of-a-kind virus-attenuation device, the Shycocan, in the UAE in the hope of helping people bring lives and businesses back to normal. And we couldn’t have found a more credible and relevant platform than the prestigious ICPM to showcase our cutting-edge technology."



Shycocan is distributed in the UAE for consumers and business customers by Redington Middle East LLC and Ibn Batuta Medicine & Medical Equipment Store LLC. It is one of the most thoroughly tested devices for both safety and efficacy. It neither uses nor emits radiation, chemicals, ozone or any toxic material. It is 100% safe for humans, animals and the environment. Additionally, it does not harm the bacterial ecosystem and microbes that thrive in the environment and are essential for our immunity.



Said the well-known scientist Dr. Rajah Vijay Kumar, the inventor of Shycocan, "Coronavirus-type outbreaks are occurring with faster intermittent frequencies. The COVID-19 strain is getting more infectious and deadlier with successive mutations in the last 17 years, underscoring the importance of a device like Shycocan. The biggest challenge of this virus is its infectivity or virulence. Breaking the chain of infectivity requires focused work on indoor environments because they carry the highest risk of transmission. In 2017, our campus in Bengaluru experienced many incidents of seasonal flu, compelling me to design, build and install the device which was later christened Shycocan. A year later, the incidence of seasonal flu was almost totally absent from the campus. When the COVID-19 pandemic struck, the device was sent for testing and regulatory compliances to global laboratories and found to be equally effective against it. It was overwhelming to realise that we had already created the world's first technology to fight the pandemic long before imagining the possibility of such a crisis taking the entire world in its grip."



Shycocan has widespread usage across market segments, including hospitals, clinics, schools, higher education institutions, banking sector, manufacturing and retail outlets, hospitality sector, government offices, real estate corporations and businesses. In addition, the company offers customised consultations, a one-year replacement warranty, strong support and service network across the UAE, and a post-installation audit.



A single device when mounted has an effective coverage area of 1,000 square feet (10,000 cubic feet). Multiple devices can be installed to cover a larger indoor space. The device has seen a robust demand from institutional buyers across the globe and is already in use in countries such as India, the US, Europe, Malaysia, Australia, New Zealand and South Africa, among others.



Dr Abdullah Al Kindi, Chairman & CEO, ICPM, said, "Mankind is facing one of the most challenging times – something that has impacted lives, livelihoods and businesses at a global scale. We as global citizens need the best of science, technology, social responsibility, and willpower to fight it – and triumph. ICPM was established with responsibility towards humanity and with healthcare as its foundation. It gives me immense pleasure to launch Shycocan on this platform. It is a product with innovative technology and the capability to bring businesses and lives back to normal."